Trials / Not Yet Recruiting
Not Yet RecruitingNCT04406727
UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial With UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- United BioPharma · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase III study is to evaluate the efficacy between treatments (UB-421 Arm vs. Placebo Arm) by measuring the proportion of subjects with reduction in HIV-1 RNA viral load.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UB-421 | UB-421 in combination with their ARV |
| OTHER | Antiretroviral (ARV) | Antiretroviral (ARV) |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2020-05-28
- Last updated
- 2023-04-24
Source: ClinicalTrials.gov record NCT04406727. Inclusion in this directory is not an endorsement.